Atrial Tachyarrhythmia Recurrence Research Articles

Impact of interatrial septal thickness and interatrial conduction time on cryoballoon ablation outcome

Abstract Introduction Interatrial septal thickness (IAST) is an indirect measure of interatrial septal fat which is anatomic extension of epicardial fat. Interatrial conduction time (IACT) reflects altered conduction between atria. Both parameters are associated with left atrial (LA) fibrosis and atrial fibrillation (AF). However, limited data exist regarding the influence of IAST and IACT on the outcomes of cryoballoon ablation (CBA). In this study, we aimed to analyze possible effect of IAST and IACT on atrial tachyarrhythmia (ATA) free survival after CBA. Methods and results Sixty five patients (34/65, 52.3% male, 53.3±11.0 years old) undergoing first time CBA for pulmonary vein isolation were enrolled. Pre-procedural TEE images were analyzed and bicaval view was used to visualize SVC rim for IAST measurement (Figure 1). IACT was measured from the onset of surface P wave to atrial EGM recorded by distal coronary sinus electrode. After 3 months blanking period all anti-arrhythmic drugs were discontinued. Clinical endpoint was ATA recurrence including AF, flutter or tachycardia lasting more than 30 seconds. After 11.2±4.1 months of follow-up 8 patients (12.3%) had ATA recurrence. IAST (4.4±1.1 vs 3.3±0.6 mm, p=0.007) and LA volume index (37.4±8.0 vs 30.1±12.4 mL/m2, p=0.03) were greater in patients with ATA recurrence than those without. In contrast, patients with and without had similar IACT (85.8±31.1 vs 62.2±23.9 ms, p=0.10). Conclusion Pre-procedural measurement of IAST using TEE may provide prognostic information in CBA patients. Increased IAST was found to be associated with ATA recurrence after CBA based PVI and warrants further study.Interatrial septal thickness measurement

Different predictors of AF recurrence after pulmonary vein isolation with cryoballoon and radiofrequency ablation: insights from clinical and electroanatomical mapping data of the NO-PERSAF study

Abstract Background Pulmonary vein isolation (PVI) with cryobaloon ablation (CBA) and radiofrequency ablation (RFA) lead to a similar outcome of freedom from atrial tachyarrhythmia (ATA) during follow-up as showed by the NO-PERSAF study. Analyses of ATA recurrence for these two techniques based on data of electroanatomical mapping (EAM) are scarce from randomized clinical trials. Purpose This study aimed to evaluate and compare clinical outcomes and EAM data recorded in the left atrium (LA) during CBA and RFA procedures in patients with persistent atrial fibrillation (AF). Methods For the NO-PERSAF study, 101 patients (mean 63.2±8.6 years, 80 male, 21 female) with persistent AF (77 persistent AF, 24 long-standing persistent AF) referred to PVI were randomized (1:1) to CBA or RFA and followed for 12 months. A prolonged 3-year follow-up was carried out. EAM was performed by a circular mapping catheter with a 3-dimensional mapping system in all patients. EAM data were recorded and analyzed off-line. The areas of the LA, posterior wall, low-voltage (<0.5mV) and complex fractionated electrogram (cycle length <120 ms) were measured and corrected by body surface area (BSA). EAM data from 90 patients were qualified for further analysis and the others (5 in CBA and 6 in RFA) excluded because of disqualification or technical failure of recording. Correlation between clinical results of 3-year follow-up and the EAM data were analyzed using univariate cox regression. Results After 3-year follow-up, freedom from ATA was achieved in 51 (50.5%) of the 101 patients, 28 (54.9%) out of 51 patients in the CBA group and 23 (46.0%) out of 50 patients in the RFA group and no difference was found (p=0.327). RFA compared with CBA resulted in larger ablation lesions in the LA (23.9% vs. 21.3%; p=0.037) and particularly in the posterior wall (44.2% vs 31.8%; p<0.001). Compared between the patients with and without recurrence, there was no difference with respect to age, gender, AF history, body mass index, heart disease and CHA2DS2-vasc score. For EAM data, the area of the LA and low voltage were significantly higher in ATA recurrent patients in CBA group, but not in RFA group (Table 1). Univariate cox regression analyses suggested that 3-year follow-up outcomes were associated with the size of the LA and the amount of low voltage corrected by BSA. The criteria of the LA area >55 cm2/m2 or low voltage area <19 cm2/m2 could predict ATA recurrence after CBA, but not after RFA procedure (Figure 1). Conclusions The size of the LA and the amount of low voltage corrected by BSA was associated with the outcomes of PVI during follow-up and could be employed as predictors of ATA recurrence for CBA, but not for RFA procedure.Table 1Figure 1K-M curves after CBA and RFA

A propensity score matched comparison of pulsed field versus hybrid ablation in patients with long standing persistent atrial fibrillation

Abstract Introduction On one hand pulsed-field ablation (PFA) has shown favourable data in terms of safety and efficiency for pulmonary veins isolation (PVI). One the other hand, hybrid ablation results in better outcomes in patients with persistent atrial fibrillation (AF), as it combines a thoracoscopic epicardial and transvenous endocardial approach in a single procedure. Purpose Aim of this study was to to compare 1-year follow-up data of patients with long standing persistent AF undergoing PVI and posterior wall isolation using PFA, and hybrid AF ablation. Methods Consecutive patients with long standing persistent AF undergoing a first PVI with PFA at our institution were included. For comparison, patients with long standing persistent AF undergoing a first PVI with hybrid ablation were selected using a 1:1 nearest neighbor propensity score matching. Hybrid AF ablation was performed in a one-step procedure: (i) thoracoscopic ablation followed by (ii) endocardial mapping and eventual ablation. All patients received PVI and posterior wall isolation in both group. Additional lesions were performed based on clinical indication and physician judgement. The primary endpoint was recurrence of atrial tachyarrhythmia after 12 months of follow-up (with a blanking period of 3 months). Results A total of 130 patients with persistent AF underwent hybrid ablation and 72 patients underwent PFA. 85 patients (age:67.5±9.7 years, 68.2% males, CHA2DS2-VASc: 2.5±1.3) with long standing persistent AF underwent their first AF ablation (PFA N= 39; Hybrid N = 46). After a 1-year follow-up, freedom from atrial tachyarrhythmia recurrence was 74.4% with PFA and 71.7% with hybrid ablation (p = 0.786). After propensity score matching, a total of 39 matched pairs of PFA and hybrid first AF ablation remained. The result remained unchanged and no significant difference was observed between treatment cohorts after matching (Figure 1, p=0.039). Conclusion In a propensity score matched analysis of patients with long standing persistent AF, freedom from any atrial tachyarrhythmia 1 year after AF ablation using PFA was favourable and at least as good as with hybrid ablation.

Comparison of pulsed field ablation and thermal ablation for repeat procedures after failed prior thermal ablation for atrial fibrillation

Abstract Background Procedural efficiency and long-term clinical outcome after a first pulmonary vein isolation (PVI) for atrial fibrillation (AF) with pulsed-field ablation (PFA) has recently been reported to be non-inferior compared to radiofrequency ablation (RFA) and cryoballoon ablation (CBA). Studies comparing PFA and RFA for a first redo procedure in patients with failed prior thermal PVI are lacking. Purpose We sought to compare procedural efficiency and 1-year success rate (i.e maintenance of sinus rhythm) between PFA and RFA in patients undergoing a first redo procedure due to recurrence of atrial tachyarrhythmias after a prior thermal PVI. Methods Patients with recurrences after a 90-day blanking period following an index PVI with either RFA or CBA referred for a first redo ablation were enrolled. All redo procedures were done using a 3D electro-anatomical mapping to identify PV reconnections and guide repeat PVI by either PFA or RFA. In cases of incomplete or ostial isolation, the PFA group was treated using the standard 8-applications per vein while the CLOSE protocol was used for segmental PVI completion in the RFA group. Extra-PV lesion sets were added at the discretion of the treating physician. Patients were followed with 7d-Holter ECGs 3, 6, and 12 months after reablation. Recurring arrhythmias were categorized as persistent AF, paroxysmal AF, or atrial flutter. Secondary endpoints were periprocedural complications, total ablation time, radiation time and exposure. Results A total of 220 patients (median age 67 [IQR 58-74] years, 64% male, 64% persistent AF) were enrolled and equally treated with PFA or RFA (110 in both groups). There were no statistically significant differences in the clinical characteristics at baseline. Procedure time was shorter in the PFA group (95 vs. 122 minutes, p=0.001) whereas radiation time and dose were higher in the PFA group (17.0 vs. 6.4 minutes, p=<0.001 and 4.9 vs. 2.2 Gycm2, p=<0.001). Additional posterior wall ablation (PFA) or roof line (RFA) was performed predominantly in the PFA group (61 patients, 55.5 %) and in 5 patients (4.5 %) in the RFA group (p=0.001). Major complications occurred in 3 patients in the PFA group and in 1 patient in the RFA group (see Picture 2). Freedom from arrhythmia in Kaplan-Meier analysis 12 months after the reablation was 61% (CI 50-74%) in the PFA group and 59% (CI 49-71%; log-rank test p=0.81). No differences in outcomes were observed in the pooled group between paroxysmal AF (60%, CI: 50-72%) and persistent AF (61%, CI: 51-73%, p=0.64). Recurrence of organized atrial tachycardia was more common in the PFA group (p=0.018) Conclusion In patients undergoing a first redo procedure after a first round of thermal PVI and with recurrence of atrial tachyarrhythmia, PFA for reablation resulted in shorter procedure times compared to RFA despite more frequent posterior wall ablation. Long-term arrhythmia-free survival after the redo procedure was similar in both groups.Kaplan-Meier analysis of redo proceduresProcedure and outcome data

Efficacy and safety of very high-power short-duration posterior wall ablation in persistent atrial fibrillation: a propensity score-matched comparison with standard power long-duration ablation

Abstract Background Catheter ablation (CA) with pulmonary vein isolation (PVI) is an optimal treatment option in patients with paroxysmal atrial fibrillation (AF). PVI alone in patients with persistent AF has proved to have suboptimal results. Ablation of additional atrial structures, such as posterior wall (PW) and left atrial appendage has been investigated as a tool to improve procedural efficacy. Recently very high-power short-duration (vHPSD) ablation was developed to allow rapid PVI, limiting complication through the maximization of resistive heating, and minimization of conductive heating. Objectives Compare PVI plus PWI using vHPSD versus standard-power (SP) ablation index-guided CA among consecutive patients with persistent AF Methods Forty consecutive patients underwent PVI plus PW isolation using vHPSD, compared to 40 controls underwent standard power (SP) PVI plus PW isolation. The primary efficacy endpoint outcome was recurrence of atrial tachyarrhythmias after a 3-month blanking period. The primary safety outcome was a composite of major complications within 30 days of CA. Results Treated patients have a median age of 62.8±9 years, 68 (85%) are male. Median left atrial volume is 42.4 (36-50) ml/m2. 61 (78.8%) patients had never undergone catheter ablation before. There are no statistically significant differences between groups. PW isolation was obtained more commonly in the vHPSD compared to the SP group (98% vs. 75%, p=0.007), despite shorter procedure and fluoroscopy times (p<0.001). Survival free from recurrent atrial tachyarrhythmias at 18 months was 68% in the vHPSD and 47% in SP groups, respectively (log-rank p=0.071), without major adverse events. The vHPSD approach was significantly associated with reduced risk of recurrent AF at multivariable analysis (HR, 0.39, p=0.030). Conclusions The results show feasibility and safety of posterior wall vHPSD ablation for persistent AF using this new temperature-controlled catheter without intraprocedural and periprocedural major complications at follow-up. vHPSD ablation for PW isolation may be more effective in term of atrial tachyarrhythmias recurrences with a trend for superior efficacy. However, this remains a single center experience in a small group of patients. Comparative trials involving greater number of patients with long-term follow-up are necessary to definitive results.

Comparative analysis of clinical outcomes in repeat ablation for recurrent atrial tachyarrhythmia following initial pulmonary vein isolation with pulsed-field ablation and cryoballoon ablation

Abstract Background While pulsed-field ablation (PFA) holds promise for the initial catheter ablation performing pulmonary vein (PV) isolation (PVI) in patients with atrial fibrillation (AF), a repeat procedure remains necessary for those experiencing recurrent atrial tachyarrhythmia (ATA). This study aimed to evaluate the clinical outcomes of repeat procedures following the initial PFA in patients with recurrent ATA by comparing that following the initial CBA. Methods Patients who underwent a second ablation for recurrent ATA following initial PVI with pentaspline PFA or cryoballoon ablation (CBA) were included. Repeat ablation utilized radiofrequency current ablation with three-dimensional mapping guidance, involving repeat PVI combined with linear ablations when necessary. Acute data, such as documented arrhythmia before the repeat procedure, the number of reconnected PVs, procedural characteristics, and clinical follow-up, were analyzed. Results In total, 110 patients underwent initially successful PVI with PFA (N = 51) and CBA (N = 59), followed by a repeat procedure for recurrent ATA with a mean time interval of 365±299 days between the two procedures. The primary indication at the repeat procedure was atrial tachycardia (AT) in the PFA group (N = 27, 53%) and AF in the CBA group (N = 47, 80%). The overall PV reconnection rate per vein was 22.1%, with no significant difference between the two groups (19.1% in PFA vs. 24.7% in CBA, P = 0.16). Repeat PVI was successfully performed in all patients with PV reconnection (41.2% in PFA vs. 55.9% in CBA, P = 0.12). PV reconnection was most commonly found at the right inferior PV in both groups (25.5% vs. CBA; 32.2%, P = 0.44). Additional substrate modification was conducted in 76.5% of the PFA group and 74.6% in the CBA group, respectively (P = 0.82). The mean follow-up period was 349±280 days. The Kaplan-Meier curve indicated no statistical significance in the 1-year arrhythmia-free survival after the repeat procedure (62.4% in PFA vs. and 73.0% in CBA group, P = 0.54, Figure). Conclusion Comparable lesion durability between the initial PVI with PFA and CBA was unveiled during the repeat ablation. The second ablation for recurrent arrhythmia following initial PFA demonstrated a favorable clinical success rate at one year after the subsequent procedure, showing no significant difference compared to repeat ablation subsequent to CBA.arrhythmia-free survival after the repe

A novel method to identify critical isthmus of right atrial reentrant tachycardia; Functional substrate mapping characteristics during sinus rhythm

Abstract Background Right atrial tachycardia (AT) is a frequent rhythm disorder in patients with atrial scar mainly due to surgical incisions or congenital heart diseases. Despite the mounting evidence about AT mechanisms and types, data is scarce regarding the conduction properties as well as functional characteristics of atrial substrate during sinus rhythm that has role in the maintenance of the tachycardia. Purpose We sought to evaluate the relationship between the functional substrate mapping (FSM) characteristics of right atrium and the critical isthmus (CI) of re-entrant ATs in patients with underlying atrial scar. Methods Among patients with the history of right AT who underwent catheter ablation with 3-D mapping were retrospectively enrolled. Voltage map and isochronal late activation mapping (ILAM) were created during sinus / paced rhythm using multielectrode catheters to detect deceleration zones (DZ). Subsequently AT was induced with programmed stimulation and activation mapping was performed to detect CI of the tachycardia. Atrial tachyarrhythmia (ATa) recurrence was defined as detection of atrial fibrillation or AT (≥ 30 s) during the follow-up. Results A total of 24 patients [mean age: 46 ±15, gender: 13 (54 %) female] with right AT were included. A total of 37 ATs were mapped [16 (43.2%); localized reentry, 21 (56.7%), macroreentry]. Atrial low voltage zones comprised 23.3 ± 13.0 % of total right atrium. The mean value of bipolar voltage, EGM duration and conduction velocity during sinus rhythm corresponding to CI of ATs were 0.18 ± 0.10 mV, 121.7 ± 29.4 ms, 0.06 ± 0.04 m/s and, respectively. Total number of DZs per chamber was 1.1 ± 0.3, which were all located in the low-voltage zone (<0.5 mV) detected by high density mapping. All CIs of non- cavo-tricuspid-isthmus (CTI) dependent reentry were colocalized with DZs detected during FSM. The positive predictive value of DZs to detect CI of inducible ATs is 80.8%. During the mean follow-up of 11.7 ± 8.1 months, freedom from ATa was 87.5%. Conclusion Although, CTI-dependent macroreentry is the most common mechanism in patients with RA scar, our findings demonstrated the relevance of FSM to predict non-CTI dependent ATs. Conduction slowing manifested as DZs with continuous-fragmented signal morphology may guide to tailor ablation strategy in case of underlying RA scar.

Radiofrequency balloon ablation: 1-year outcomes of the AURORA registry

Abstract Background and Objectives A novel irrigated radiofrequency balloon (RFB) for pulmonary vein isolation (PVI) integrated into 3D mapping system was recently launched. Methods Patients ablated for paroxysmal atrial fibrillation (PAF) or persistent atrial fibrillation (persAF) at two German high-volume electrophysiology centers were included into the prospective AURORA registry. All patients underwent clinical follow-up (FU) at 90, 180 and 360 days following ablation including 24h Holter ECGs. Results A total of 101 patients were enrolled (50 from centre A, 51 from centre B) and 86 patients (48% male, 65 ± 11 years, 55% PAF, 59 ± 7% left ventricular ejection fraction (LVEF)) completed the follow-up. Mean ablation and procedure times were 26 ± 13 min and 71 ± 20 min, respectively. Dose area product was 1501 ± 1634 mGycm2. Acute PVI was achieved in 100%. Atrial fibrillation (AF) free survival after a mean FU of 361 (219-375) days was 78.4% for PAF and 75.4% for persAF. (p= 0.828). A multiple regression analysis did not reveal any clinical or procedural predictors of AF recurrence among sex, age, BMI, left atrial diameter, LVEF, ablation time, procedure time and single shot PVI. However, early recurrence of atrial tachyarrhythmia (ERAT) was an independent predictor for AF recurrence at 1-year (Hazard Ratio [HR]: 3.198; 95% confidence interval [95% CI]: 1.036 - 10.32, p value = 0.0433). Primary adverse events occurred in 3.5% of patients (1 postprocedural pharyngeal bleeding, 1 myocardial infarction, 1 non-cardiovascular death); no pericardial effusion, stroke or phrenic nerve paralysis were observed. Conclusions RFB-based PVI is clinically effective and safe. ERAT at the first follow-up visit is an independent predictor of late AF recurrence.

Impact of early recurrences on late recurrences after pulmonary vein isolation with pulsed field ablation. A subanalysis from the EU-PORIA multicenter international registry

Abstract Background Early recurrences of atrial tachyarrhythmia (ERAT) are commonly observed after pulmonary vein isolation (PVI) with thermal energies. ERAT during the 90-day blanking period (BP) should not be considered therapy failure as the cardiac tissue is still healing and the long-term benefit of PVI may not be immediately apparent. With the introduction of pulsed field ablation (PFA), a non thermal, myocardial-specific ablation technology for atrial fibrillation (AF), the significance of ERAT following PVI is unclear. Methods EU-PORIA (EUropean real-world outcomes with Pulsed field ablatiOn in patients with symptomatic atRIAl fibrillation), a multicentre international registry, collected data from 1233 patients treated with the pentaspline PFA catheter. For the current analysis, patients with a previous AF ablation procedure, patients treated with lesions beyond PVI, and patients without complete follow up data (during and following the BP) were excluded. The rate and significance of ERAT following PFA PVI were analysed. Results This subanalysis included 1011 patients (38% female, 66±11 years old, 64% paroxysmal atrial fibrillation [PAF]). ERATs were recorded in 178/1011 (18%) of patients (16% in PAF and 21% in persAF, p=0,021). Notably, ERAT patients were older (67,1±11,4 Vs 65,4±10,9, p=0,015) and had a higher median CHA2DS2-VASc Score (2,5 [IQR:1-4] Vs 2 [IQR:1-3]; p=0,019). The 35-mm catheter was more often used in ERAT patients (48/178(27%) Vs 148/833(18%) – p=0,005). At a median follow-up of 365 days (IQR 347-390), 100/178(56%) of patients with ERAT had documented late recurrence (LR), compared to only 147/833(18%) of patients in sinus rhythm throughout BP (p<0,001). Kaplan Meier estimates for overall freedom from AF/AT outside of the BP was 77% at one year for all patients. Patients with ERAT had a significantly lower freedom from AF/AT compared to patients with no ERAT (42% vs 84%, log-rank p<0,001). The absence of ERAT was associated with long-term success independent of the type of AF (41% Vs 88% in PAF, 43% vs 74% in persistent AF; p<0,001 for both). Among ERAT patients, no additional predictors for LR were identified. Conclusions In this large multicentre international registry, early recurrence of atrial tachyarrhythmia following PFA PVI were recorded in 18% of patients. ERAT was associated with late recurrences in the majority of cases, independent of AF type. The need for a blanking period following non thermal energy ablation for atrial fibrillation should be further questioned.

The new "olive strategy" for pulsed field ablation of atrial fibrillation: procedural data and early follow-up

Abstract Background Pulsed field ablation (PFA) is a new myocardial-specific ablation technology for atrial fibrillation (AF). Direct current electric energy is applied to cells and disrupts cell membranes by creating pores. Purpose The aim of this single-center study was to report procedural data and early recurrence of atrial tachyarrhythmia (ERAT) following a new PFA-based ablation strategy for pulmonary vein isolation (PVI). Methods Consecutive patients with symptomatic AF were enrolled to undergo PFA-PVI using the pentaspline catheter. A new ablation strategy was performed: In total 10 applications per pulmonary vein (PV) were delivered. In addition to the conventional four applications in flower- and four applications in basket-configuration, two applications were delivered in a smaller "olive"-configuration. ERAT was defined as any documented AF/atrial tachycardia (AT) lasting more than 30 seconds during a 90-days blanking period. Procedural and demographic data were analysed. Results 60 patients (37% female, age 67±12, 43% paroxysmal atrial fibrillation [PAF]) were included in this preliminary analysis. 239 PVs were identified, and all PVs could be isolated using solely the PFA device. All PVs were isolated with the first application. 40 applications per patient were delivered. No complications occurred. Procedure time was 30±11 min, fluoroscopy time was 6±3 min. Median follow-up time was 100 days. 20% of patients experienced an early recurrence after a median of 2 days (IQR 1-7.25; 92% AF, 8% AT). Kaplan Meier estimated freedom of AF/AT was 83.3 % at 3 months, 92.3% for PAF and 76.5% for persistent atrial fibrillation (p=0.11). Conclusions Our data show feasibility of a new ablation strategy with the pentaspline PFA-catheter. This study indicates high acute efficacy and safety. 83.3% of patients are free of AF/AT at 3 months. Longer follow-up times are needed to assess the clinical outcome and will be available at the time of presentation.

Ten-year follow-up results of patients with persistent atrial fibrillation treated by combined pulmonary vein isolation and complex fractionated atrial electrocardiogram ablation

Abstract Background For persistent atrial fibrillation (AF), pulmonary vein isolation (PVI) alone is associated with lower success rate compared to paroxysmal AF and additional strategies are needed. Ablation targeting on complex fractionated atrial electrograms (CFAE) is an alternative method. Although clinical benefits of the strategy combined PVI and CFAE ablation have not been shown by large trials, clinical situations and consequences of this approach have not been clearly demonstrated during very long term follow-up. Purpose This study aimed to retrospectively investigate clinical outcomes of patients with persistent AF treated by the approach combined PVI and CFAE ablation during a follow-up period of 10 years. Methods 73 patients (59.4±8.1 years, 64 male, AF history 5.5 years) with persistent (23, 31.5%) and long-standing persistent AF (50, 68.5%) who underwent combined PVI and CFAE ablation in the first procedure were included. Structural heart disease was found in 9 patients, and a history of ablation for typical atrial flutter (AFL) in 4. A complete CFAE mapping in the left atrium and coronary sinus was performed with a 3-D mapping system (EnSite NavX). All CFAEs defined as electrograms with continuous activities or mean cycle length detected by the system <80 ms were eliminated. All patients were controlled regularly during the first year with 12-lead ECG and Holter monitoring and followed by annual control. The electronic health records for all patients were extensively investigated and the patients were interviewed in 2020-2022. Any documented atrial tachyarrhythmia (ATA) after 3-month blanking period was regarded as recurrence. Results Mean 2.2±1.2 (1-5) ablation procedures were performed in each patient. After index ablation, 18 (24.7%) were free of ATAs during 10-year follow-up. 26 (35.6%) had recurrence of only AF, 6 (8.2%) of only AFL and 23 (31.5%) had both AF and AFL. The proportion of AFL was 39.7% with 6 typical AFL. After multiple ablation procedures, 33 (45.2%) patients were free of ATA during the follow-up. 23 (31.5%) had recurrence of only AF, 5 (6.8%) of only AFL and 12 (16.4%) of both AF and AFL. The proportion of AFL was 23.2% with no typical AFL. At 1-year follow-up, freedom of ATAs in persistent AF was higher than that in long-standing AF (65.2 vs. 40.0%, p=0.033) and no significant difference was found after 2 years (47.8 vs. 34.0%, p=0.129) until 10 years (30.4 vs. 22.0%, p=0.167, Figure 1). No difference was observed between these subgroups after multiple procedures at 10-year follow-up (47.8 vs. 44.0%, p=0.708, Figure 2). Conclusions PVI plus CAFE ablation in patients with persistent AF led to a high recurrence of ATA after index ablation. Difference of ATA-freedom between persistent and long-standing persistent AF groups was found only 1 year after the index procedure, but not during further follow-up. Incidence of post-ablation AFL was particularly high, even after multiple ablation procedures.Figure 1Figure 2

Staged hybrid convergent procedure versus pulsed field ablation for pulmonary veins and posterior wall isolation in the treatment of atrial fibrillation

Abstract Background There are limited effective treatment options for persistent atrial fibrillation (AF) patients, with pulmonary veins (PV) isolation alone being considered suboptimal for many patients. Hybrid convergent ablation has been shown to improve clinical outcomes when compared to an endocardial-only radiofrequency (RF) strategy. Pulsed field ablation (PFA) has recently gained growing interest for its efficacy and safety profile in PV and posterior wall (PW) ablation. Objectives To compare clinical outcomes of hybrid convergent RF ablation versus endocardial PFA for PV and PW isolation in patients with persistent AF. Methods From July 2022, 86 persistent AF consecutive patients, receiving endocardial PFA of PV and PW (PFA group, N = 44) or receiving hybrid convergent RF ablation (Hybrid group, N = 42) at our institution were enrolled. Recurrence was defined as any atrial tachyarrhythmia following the 3-month blanking period. Results No differences were found between PFA and Hybrid groups regarding age (PFA 66.0±7.4 years vs Hybrid 63.9±10.6 years; p=0.193) and left atrial volume index (PFA 45.5 [36.7-57.2] ml/m² vs Hybrid 45.0 [39.2-59.7] ml/m²; p=0.920). Differences regarding left ventricular ejection fraction were borderline significant among groups (PFA 55.0 [49.5-62.0]% vs Hybrid 60.5 [52.3-65.0]%; p=0.048), both showing an overall normal LV function. There were no significant differences regarding AF duration (PFA 38.0 months [IQR: 19.2 to 99.0 months] vs Hybrid 70.0 months [IQR: 46.0 to 118.0 months]; p = 0.063). Redo ablation patients’ rate was higher in the hybrid group (PFA n=16, 36.4% vs Hybrid n=28, 66.6%; p<0.001). Procedure duration was Ionger in the hybrid group (179.9±60.1 minutes) compared to PFA endocardial ablation (PFA 106.2±30.7 minute; p<0.01). After a median follow-up of 233.0 [179.0–331.8] days, there was no difference in atrial tachyarrhythmias recurrence rate (PFA n=11, 25.0% vs Hybrid n=10, 23.8%; p=0.897); no difference in the antiarrhythmic drug use rate was found (PFA n=24, 54.5% vs Hybrid n=19, 45.2%; p=0.388). Conclusions PFA of PV and PW, compared with the hybrid convergent ablation strategy, is an endocardial-only, less invasive, and faster procedure. 6-month rhythm outcomes were similar in both groups.

Optimized workflow for pulmonary vein isolation using very high power short duration radiofrequency ablation

Abstract Background Point-by-point radiofrequency ablation is the most used invasive treatment of atrial fibrillation (AF). However, single-shot technologies are largely widespread due to their proved safety and efficacy. QDOT MICRO (QDM) is a novel contact force–sensing catheter optimized for temperature-controlled radiofrequency (RF) ablation that allows to maintain target temperature during 90 W ablations for ≤4 seconds. Purpose This study evaluates procedural safety and effectiveness as well as long-term effects of an optimized procedural workflow using QDM catheter to perform wide atrial circumferential ablation in patients with paroxysmal AF. Methods Consecutive patients referred for paroxysmal AF first ablation through pulmonary vein isolation (PVI) were prospectively enrolled. Every procedure was performed in general anesthesia by using CARTO3 Electroanatomical Mapping System BiosenseWebster QDM catheter and Deflectable Sheet VIZIGO as single sheet in left atrium. VHPSD was performed to encircling the posterior wall, while conventional-power temperature-controlled (CPTC) mode was used to encircling the anterior wall. The primary safety endpoint was incidence of primary adverse events within ≤7 days of ablation. The primary effectiveness endpoint was freedom from documented atrial tachyarrhythmia recurrence and acute procedural, repeat ablation, and antiarrhythmic drug failure. Results 120 enrolled participants (61 ± 12 years, 45% female) met eligibility criteria. Median procedural skin-to-skin time and RF application for ablating PVs were 56 and 17 minutes, respectively. Median ablation time was 22 minutes. First-pass isolation (entrance and exit block validation) was obtained in 98 % and inter-lesion distance was 4,8 ± 0,8 mm. In 100% of patients PVI was obtained without adverse events. The Kaplan-Meier estimated 12-month rate for clinical success (freedom from symptomatic recurrence of AF) was 93%, freedom from AF was 89% Conclusions PVI performed with point by point optimized workflow using VHPSD RF catheter in combination with steerable sheet is highly efficient and effective without compromising safety.

Durability of pulmonary vein isolation after radiofrequency-balloon ablation

Abstract Aims Recently a multi-electrode radiofrequency balloon (RFB) for pulmonary vein isolation (PVI) was introduced. To the best of our knowledge no data on PVI durability has yet been published. Objectives The aim of this single-center study was to investigate the incidence of pulmonary vein (PV) reconnectionafter RFB-guided PVI. Methods Patients undergoing second ablation for recurrent atrial tachyarrhythmia (ATa) following the initial RFB-PVI were investigated. Left arial (LA) electroanatomic mapping was used. The rate of PV reconnection, the type of recurrent ATaand procedural data were analyzed. Results Among 178 patients treated with RFB, 21 patients underwent a second procedure 11 ± 6 months after the initial PVI. 67% of these patients presented with atrial fibrillation (AF), 33% with atrial tachycardia. Regarding baseline characteristics, 71% of these patients were male, mean age was 67±10, mean BMI was 28±5, 67% had hypertension and 33% had coronary artery disease. Overall, 83 PVs including one left common PV (LCPV) were assessed. The rate of PV reconnection was 28% (23/83 PVs). 57% of patients (12/21) had at least one reconnected PV. Patient with PV-reconnection had more AF recurrence and less often atrial tachycardia (AT) (AF: 75%, AT: 25%) than patients with durably isolated PVs (AF: 56%, AT: 44%). Most reconnections were detected in septal PVs. Reconnections were distributed as follows: RIPV: 8/21, RSPV: 7/21, LIPV: 5/20, LSVP: 3/20, LCPV: 0/1. Precise localization of the gaps could be identified in 15/23 PVs. Most common gap locations were at the anterior carina (4/15) for septal PVs and anterior-inferior (3/15) at the LIPV. Ablation strategy was pure PV reisolation in 8/12 patients and PV reisolation with additional linear lesions in 4/12 patients. All patients with durably isolated PVs were treated with additional substrate modification. In total, following additional lesions were set: anterior line: 6, roof line: 11, cavotricuspid isthmus (CTI): 7, LAA-Isolation: 1, free wall of the right atrium: 1. Regarding procedural data of the index procedure, the number of applications was not a statistically significant predictor of reconnection (p=0.77). Conclusion We provide the first insight into durability of PVI after radiofrequency-balloon ablation. 72% of all PVs were still isolated. Our data on gap localization might help to identify regions where optimal balloon contact is difficult to achieve. More data on this topic might reveal predictors for PV reconnections.

Pulmonary Vein Isolation for Atrial Fibrillation: Comparison of a Very High-Power Very Short-Duration (vHPvSD) Ablation Protocol versus a Hybrid Ablation Approach-Procedural and Mid-Term Outcome Data.

Background: Pulmonary vein isolation (PVI) using radiofrequency ablation (RFA) is a standard-of-care treatment in the rhythm control strategy of symptomatic atrial fibrillation (AF). Ablation protocols, varying in the power and duration of energy delivery, have changed rapidly in recent years. Very high-power very short-duration ablation (vHPvSD) is expected to shorten procedural times compared to conventional ablation approaches. However, the existing data suggest that this might come at the cost of lower first-pass isolation rates, a predictor of poor ablation long-term outcomes. This study aims to compare a vHPvSD protocol to a hybrid strategy, in which the power and duration of the energy transfer are adapted depending on the anatomical location. Methods: We retrospectively analyzed procedural and outcome data from 93 patients (55 vHPvSD vs. 38 hybrid) scheduled for de novo pulmonary vein isolation. A vHPvSD ablation protocol (90 Watt (W), 4 s) was compared to a hybrid protocol using vHPvSD on the posterior wall and 50 W HPSD (high-power short-duration) ablation guided by the Ablation Index along the remaining spots. Results: Ablation times were significantly shorter in the vHPvSD cohort (5.4 min. vs. 14.2 min, p < 0.001), thus resulting in a significant reduction in the overall procedural duration (91 min vs. 106 min, p = 0.003). The non-significant slightly higher first-pass isolation rates in the vHPvSD cohort (85% vs. 76%, p = 0.262) did not affect freedom from AF 6 months after the procedure (83% vs. 87%, p = 0.622). Conclusions: vHPvSD helps in shortening the PVI procedural duration, thus neither affecting first-pass isolation rates nor freedom from atrial tachyarrhythmia recurrence at 6 months after the index procedure.

PolarX vs Arctic Front for Cryoballoon Ablation of Paroxysmal AF: The Randomized COMPARE CRYO Study.

Pulmonary vein isolation is an effective treatment for atrial fibrillation (AF). Cryoballoon ablation using the Arctic Front cryoballoon (Medtronic) was found to be superior to antiarrhythmic drug treatment. Recently, a novel cryoballoon system was introduced (PolarX, Boston Scientific). The purpose of this study was to compare the efficacy and safety of the 2 cryoballoons in a randomized controlled trial. Patients with symptomatic paroxysmal AF were enrolled in 2 centers and randomized 1:1 to pulmonary vein isolation using the PolarX or the Arctic Front cryoballoon. All patients received an implantable cardiac monitor. The primary endpoint was first recurrence of atrial tachyarrhythmia (AF, atrial flutter, or atrial tachycardia [AT]) between days 91 and 365. Procedural safety was assessed by a composite of tamponade, phrenic nerve palsy lasting >24 hours, vascular complications, stroke/transient ischemic attack, atrioesophageal fistula or death up to 30days. A total of 201 patients were enrolled. At 1 year, recurrence of atrial tachyarrhythmia had occurred in 41 of 99patients (41.6%) assigned to the PolarX group and in 48 of 102 patients (47.1%) assigned to the Arctic Front group (HR: 0.85 [95%CI: 0.56-1.30]; P = 0.03 for noninferiority; P = 0.46 for superiority). The safety endpoint occurred in 5patients (5%) in the PolarX group (n=5 phrenic nerve palsies lasting >24 hours), whereas no safety endpoints occurred in the Arctic Front group (P = 0.03). In this randomized controlled trial using implantable cardiac monitors for continuous rhythm monitoring, the novel PolarX cryoballoon was noninferior compared with the Arctic Front cryoballoon regarding efficacy. However, the PolarX balloon resulted in significantly more phrenic nerve palsies. (Comparison of PolarX and the Arctic Front Cryoballoons for PVI in Patients With Symptomatic Paroxysmal AF [COMPARE-CRYO]; NCT04704986).

Adjunctive low-voltage area ablation for patients with atrial fibrillation: An updated meta-analysis of randomized controlled trials.

The efficacy and safety of adjunctive low-voltage area (LVA) ablation on outcomes of catheter ablation (CA) for atrial fibrillation (AF) remains uncertain. PubMed, Embase, Cochrane Library, and ClinicalTrials.gov were searched for randomized controlled trials (RCTs) comparing CA with versus without LVA ablation for patients with AF. Risk ratios (RR) with 95% confidence intervals (CI) were pooled with a random-effects model. Our primary endpoint was recurrence of atrial tachyarrhythmia (ATA), including AF, atrial flutter, or atrial tachycardia. We used R version 4.3.1 for all statistical analyses. Our meta-analysis included 10 RCTs encompassing 1780 patients, of whom 890 (50%) were randomized to LVA ablation. Adjunctive LVA ablation significantly reduced recurrence of ATA (RR 0.76; 95% CI 0.67-0.88; p < .01) and reduced the number of redo ablation procedures (RR 0.54; 95% CI 0.35-0.85; p < .01), as compared with conventional ablation. Among 691 (43%) patients with documented LVAs on baseline substrate mapping, adjunctive LVA ablation substantially reduced ATA recurrences (RR 0.57; 95% CI 0.38-0.86; p < .01). There was no significant difference between groups in terms of periprocedural adverse events (RR 0.78; 95% CI 0.39-1.56; p = .49). Adjunctive LVA ablation is an effective and safe strategy for reducing recurrences of ATA among patients who undergo CA for AF.

Obesity is associated with long-term outcome of catheter ablation of atrial fibrillation in patients with dilated cardiomyopathy.

Patients with atrial fibrillation (AF) and dilated cardiomyopathy (DCM) often exhibit cardiac dysfunction and a poor prognosis. However, the specific reasons are unclear. This study aimed to describe the impact of obesity in patients with AF and DCM. Seventy-four consecutive patients with AF and DCM were enrolled and classified by body mass index. We measured primary endpoints, including cardiac death, recurrent AF, recurrent atrial tachyarrhythmia and stroke, as well as secondary endpoints. In multivariate analysis, compared to the normal-weight group, the overweight and obese groups had greater incidences of recurrent AF (0.0 vs 30.3 vs 40.0%, respectively, log-rank p = 0.048) and rehospitalisation (9.1 vs 36.4 vs 45.0%, respectively, log-rank p = 0.035). Compared to the normal-weight group, five-year outcomes for primary endpoints were inferior in the overweight and obese groups (18.2 vs 30.3 vs 50.0%, respectively, log-rank p = 0.042). Overweight patients exhibited more benefit in recovery of left ventricular ejection fraction after ablation (from 39.1 to 50.0%, p = 0.005) than the normal-weight group (from 43.1 to 52.3%, p = 0.199) and obese group (from 44.9 to 51.2%, p = 0.216). Patients with AF and DCM with overweight or obesity exhibited worse long-term outcomes in recurrent AF than normal-weight patients. However, overweight patients showed the most benefit in cardiac function after ablation.

Early atrial fibrillation recurrence post catheter ablation: Analysis from insertable cardiac monitor in the era of optimized radiofrequency ablation

BackgroundEarly recurrence of atrial tachyarrhythmia (ERAT) is associated with ablation-induced proarrhythmogenic inflammation; however, existing studies used intermittent monitoring or nonoptimized radiofrequency (RF) applications (noncontiguous or without ablation index target value). ObjectiveThe purpose of this study was to investigate the relationship between ERAT and late recurrence based on insertable cardiac monitor (ICM) data. MethodsWe compiled data from Close-To-Cure and Close Maze studies, which enrolled patients who underwent RF ablation for paroxysmal or persistent atrial fibrillation (AF). All patients were implanted with an ICM 2–3 months before ablation. ResultsWe studied 165 patients (104 with paroxysmal AF, 61 with persistent AF). Over the 1-year follow-up period, 41 of the patients experienced late recurrence. The risk of late recurrence was higher in patients experiencing ERAT (hazard ratio [HR] 6.2; 95% confidence interval [CI] 3.0–13.0), with negative and positive predictive values of 90.5% and 45.7%, respectively. Median burden of AF during the blanking period was significantly higher in patients with late recurrence (7.9% [0.0%–99.6%]) compared to those without recurrence (0.0% [0.0%–6.0]; P <.001). For each 1% increase in AF burden during the blanking period, late recurrence increased by 4.6% (HR 1.046; 95% CI 1.035–1.059). The best tradeoff for predicting AF from ERAT occurrence was AF burden of 0.6% and last ERAT at 64 days. ConclusionIn patients ablated for paroxysmal and persistent AF with a durable RF lesion set and implanted with a continuous monitoring device, postablation early AF recurrence and burden significantly predict late recurrence. The post–AF ablation blanking period should be reduced to 2 months.

Analysis of the endocardial stage of treatment of tachyarhythmias after open interventions for atrial fibrillation. Experience of one center

AIM: To study EFI parameters and features of recurrent atrial tachyarrhythmias in patients who underwent surgical correction of AF.&#x0D; MATERIALS AND METHODS: from January 2013 to December 2021, 447 combined interventions were performed to eliminate AF using the labyrinth-3 and left atrial labyrinth techniques with correction of CHD (congenital heart disease) and/or coronary artery disease.&#x0D; Rhythm disturbances were detected in 57 (12.7%) patients at various follow-up periods. Endovascular interventions were performed in 39 patients. The average follow-up period after the endocardial stage was 34.37 (standard deviation 24.32) months. The median age of patients was 64 (58–67) years, 21 (54%) were men. The patients were divided into 2 groups: group 1 — after the classic biatrial (BA) labyrinth-3 — 23 (59%) patients, group 2 — after the left-atrial variant (LA) labyrinth-3 — 16 (41%) patients.&#x0D; At the endocardial stage, electrophysiological studies (EFI) were performed to clarify the mechanism of arrhythmia, and ablation eliminated tachyarrhythmia. EFI protocol: revision of the pulmonary veins, determination of the isolation of the posterior wall of the LA assessment of atrial arrhythmia, elimination of arrhythmia, control induction of arrhythmia after ablation. After repeated intervention, patients were observed in the operating clinic every 3 months.&#x0D; RESULTS: After the endocardial stage, a regular rhythm was determined in 19 (82.6%) patients of the BA group, 13 (92.9%) patients of the LA group (p = 0.914). Relapses in the form of AF were noted in 5 patients (4 — group 1 and 1 — group 2) group (p = 0.306) All relapses of tachyarrhythmia with an irregular cycle (AF) were detected in patients with AF before the endovascular stage In both groups, there were cases of restoration of conduction in the pulmonary veins — 10 (43.5%) patients after BA ablation and 1 (5.3%) patient after LA ablation. There are no recurrences of atrial arrhythmia after ablation of atrial flutter (arrhythmia with a stable cycle).&#x0D; CONCLUSION: The endocardial stage is highly effective and demonstrates subsequent freedom from atrial arrhythmia in patients who have tachycardia with a regular cycle after both methods of surgical ablation of AF. Recurrent tachyarrhythmia in the form of AF (irregular cycle) is associated with a low probability of maintaining a regular atrial rhythm after a repeated endocardial procedure, due to the presence of structural and electrophysiological changes in the atrial myocardium.